Research on aging and cognitive impairment in China
A Longitudinal Study on the Aging of Health and Cognitive Impairment in China
This study is trying to understand how health and thinking skills change as people get older in China, especially among the elderly, to help create better support and treatments for aging-related issues.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20000 (estimated) |
| Sex | All |
| Sponsor | First Affiliated Hospital of Wenzhou Medical University Academic / other |
| Locations | 1 site (Wenzhou, Zhejiang) |
| Trial ID | NCT06679296 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate health and cognitive changes across different age groups in China, focusing on the elderly population. It will recruit participants from hospitals, schools, and communities, conducting detailed medical examinations that include physiological checks, psychological assessments, and cognitive function screenings. The study seeks to establish a comprehensive database on aging and cognitive impairments, utilizing advanced omics approaches to identify biomarkers and develop personalized interventions. The ultimate goal is to support healthy aging policies and improve management strategies for aging-related diseases.
Who should consider this trial
Good fit: Ideal candidates for this study include individuals from various age groups, particularly those aged 60 and older, who can provide informed consent and complete the required assessments.
Not a fit: Patients with terminal diseases or substance abuse issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for promoting healthy aging and managing cognitive impairments in the elderly.
How similar studies have performed: Other studies focusing on aging and cognitive impairment have shown promise, but this specific approach utilizing a large cohort and advanced omics techniques is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Ability to sign an informed consent form: Participants and/or their legally authorized representatives, in case of diminished decision-making capacity, are capable of reading, understanding, and providing written informed consent as per national legal requirements. 2. Capability to complete assessments independently or with assistance. 3. Willingness and ability to fulfill all study requirements, including peripheral organ function assessments, EEG, lumbar puncture, MRI, and PET imaging examinations. 4. Agreement to participate in follow-up visits. Exclusion Criteria: 1. Terminal stage of significant diseases such as malignant tumors or autoimmune diseases at enrollment; 2. Substance abusers.
Where this trial is running
Wenzhou, Zhejiang
- The First Affiliated Hospital of Wenzhou Medical University — Wenzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Sipei Pan Dr.
- Email: pansipei@wmu.edu.cn
- Phone: 86+13758710622
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.